Uploaded July 2026 | Updated September 2026, 1 week ago

---

In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but with an increased risk of grade 3 or higher adverse events.

Read the full phase 3 LITESPARK-022 trial results and Research Summary at NEJM.org.

#oncology #nephrology #nejm